Fewer than a tenth of patients eligible to benefit from GLP-1 drugs like Wegovy have access to them, states the World Health Organization as it releases its initial advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for more widespread and fairer access to GLP-1 medication.
According to projections, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"The new guidelines affirms that excess weight is a lifelong illness that can be addressed with holistic and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are key obstacles to widespread availability to the jabs that can help people shift considerable body mass, says the body.
Skinny Jab Scarcity
Even in the present best projected case, the supply of such drugs could only cover around 100 million people – fewer than 10% of those who need them, as stated by the WHO.
The guideline encourages nations and manufacturers to expand availability, through strategies like patent sharing.
A patent on the active ingredient – the primary component of a leading brand – is due to expire in several nations in 2026.
How Obesity Jabs Function
The injections replicate a biological compound to reduce digestion speed, curb appetite and enhance satiety so people reduce food intake.
People typically start to lose weight within a few weeks of beginning the regular doses.
Research points to users may regain a significant portion a year later of discontinuing the drug, when their normal hunger come back.
Being overweight or obese elevates your likelihood for experiencing medical conditions, such as diabetes, heart disease, stroke, and specific cancers.
Obesity impacts individuals in every country and was responsible for over three and a half million fatalities worldwide in 2024, as per the WHO.
